Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015695 (fatty liver)
 13,941 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This study examined the relationship between volatile sulfur compounds (VSCs), including hydrogen sulphide (H(2)S), methyl mercaptan (CH(3)SH) and dimethyl sulphide [(CH(3))(2)S], in mouth air of patients and a history of systemic disease. The subjects were 387 residents (174 males and 213 females) of Fukuoka Prefecture, Japan, who participated in an oral and systemic health survey for elderly persons (mean age: 61.8, s.d. 2.8 years). The VSCs were measured using a portable gas chromatograph (OralChroma). The H(2)S concentrations were significantly greater in the 132 subjects with a history of hypertension and the 41 subjects with a history of respiratory disease, including pneumonia, pulmonary emphysema and bronchitis, than in those without such a history. The CH(3)SH concentrations were significantly greater in those with a history of hypertension. The 16 subjects with a history of cerebrovascular disease, including intracerebral haemorrhage, cerebral infarction, and subarachnoid haemorrhage, and the 58 subjects with a history of liver disease, including hepatitis, alcoholic liver disease, drug-induced liver injury, fatty liver and liver cirrhosis, showed significantly greater (CH(3))(2)S concentrations (p < 0.05). These results suggest an association between the production of VSCs in mouth air and systemic diseases such as hypertension as well as respiratory, cerebrovascular and liver diseases.
 ...
PMID:Relationship between volatile sulfur compounds in mouth air and systemic disease. 2138 56

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the least deadly but most infectious coronavirus strain transmitted from wild animals. It may affect many organ systems. Aim of the current guideline is to delineate the effects of SARS-CoV-2 on the liver. Asymptomatic aminotransferase elevations are common in coronavirus disease 2019 (COVID-19) disease. Its pathogenesis may be multifactorial. It may involve primary liver injury and indirect effects such as "bystander hepatitis," myositis, toxic liver injury, hypoxia, and preexisting liver disease. Higher aminotransferase elevations, lower albumin, and platelets have been reported in severe compared with mild COVID-19. Despite the dominance of respiratory disease, acute on chronic liver disease/acute hepatic decompensation have been reported in patients with COVID-19 and preexisting liver disease, in particular cirrhosis. Metabolic dysfunction-associated fatty liver disease (MAFLD) has a higher risk of respiratory disease progression than those without MAFLD. Alcohol-associated liver disease may be severely affected by COVID-19-such patients frequently have comorbidities including metabolic syndrome and smoking-induced chronic lung disease. World Gastroenterology Organization (WGO) recommends that interventional procedures such as endoscopy and endoscopic retrograde cholangiopancreatography should be performed in emergency cases or when they are considered strictly necessary such as high risk varices or cholangitis. Hepatocellular cancer surveillance may be postponed by 2 to 3 months. A short delay in treatment initiation and non-surgical approaches should be considered. Liver transplantation should be restricted to patients with high MELD scores, acute liver failure and hepatocellular cancer within Milan criteria. Donors and recipients should be tested for SARS-CoV-2 and if found positive donors should be excluded and liver transplantation postponed until recovery from infection.
 ...
PMID:WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. 3323 11